TP53 mutations are crucial in cancer development and treatment response, influenced by genetic and environmental factors. In CLL and AML, TP53 serves as a significant prognostic marker, affecting ...

Dalpiciclib combined with chidamide and letrozole as neoadjuvant therapy for HR-positive, HER2-negative early or locally advanced breast cancer: A single-arm, prospective, exploratory clinical study.

Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics. Among them, the Y220C mutation is the ninth most frequent and it ...

The Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) tablets and capsules in combination with Venclexta (venetoclax) for adults with chronic lymphocytic leukemia (CLL) or ...

Autologous T-Cell Therapies in Solid Tumor Malignancies: Current Landscape and Future Opportunities Histology-agnostic therapies: by focusing on common mutations across various cancers, this approach ...

CGP identifies TP53 and SMAD4 mutations as negative prognostic markers, while PTEN mutations correlate with improved survival in CRC patients. Despite no significant survival advantage, CGP-guided ...

Circulating tumor DNA may be an effective biomarker for stratifying patients with small cell lung cancer who would benefit from more stringent follow-ups and clinical trial participation.Patients who ...